Wanli Tang represents pharmaceutical and biotechnology companies of all sizes on the procurement and protection of intellectual property. She develops and manages global patent portfolios for clients and coordinates strategies to meet clients' IP needs and business goals. With an in-depth understanding of cutting-edge discoveries in fields including cancer immunology, gene editing, precision medicine, Wanli counsels on issues including patentability, validity, enforceability, infringement, and freedom-to-operate. She also assists client with investment- and public offering-related diligence investigations.  Her representative clients include Abbvie, Celgene, Merial, NGM Biopharmaceuticals, Kura Oncology, Inova Diagnostics, Fate Therapeutics, and Bellicum Pharmaceuticals.